Visit your local Alkaloid website

As an international generic pharmaceutical company, ALKALOID AD Skopje aims to be present in all segments of the industry and provide healthcare systems and patients with access to a wide range of medications at affordable prices. In addition to offering generic medicines, ALKALOID AD Skopje has set a strategic objective to introduce biosimilar drugs to the market.

To capitalize on this growing business segment in the pharmaceutical industry, ALKALOID AD has decided to invest in the South Korean company Rophibio by acquiring a minority stake, which was facilitated by the recapitalization of its newly established subsidiary, ALKALOID Pharma International in Croatia. This investment in South Korea amounting to 1 million USD will provide ALKALOID AD with an ownership share in the company and the right of first refusal when licensing products in its operating regions.

Considering the market potential and the expertise of the Rophibio team, ALKALOID AD has decided to invest in this research and development company, which is currently in the advanced stages of developing biosimilar drugs.